Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology

Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the U.S. Food and Drug Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) in August 2011, merely 4 years after the first publication of ALK-rearranged NSCLC. The crizotinib approval...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ou, Sai-Hong Ignatius, Bartlett, Cynthia Huang, Mino-Kenudson, Mari, Cui, Jean, Iafrate, A. John
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
Academia-Pharma Intersect
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500356/
https://ncbi.nlm.nih.gov/pubmed/22989574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0311
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky